biote (BTMD) to Release Quarterly Earnings on Wednesday

biote (NASDAQ:BTMD - Get Free Report) is expected to announce its Q1 2025 earnings results after the market closes on Wednesday, May 7th. Analysts expect the company to announce earnings of $0.06 per share and revenue of $47.25 million for the quarter.

biote Stock Performance

Shares of BTMD stock opened at $3.54 on Wednesday. The company has a market capitalization of $193.67 million, a price-to-earnings ratio of 13.62 and a beta of 1.17. The company has a 50-day simple moving average of $3.75 and a 200 day simple moving average of $5.03. biote has a 52 week low of $3.04 and a 52 week high of $8.44.

Analyst Upgrades and Downgrades

Separately, Craig Hallum lowered their target price on shares of biote from $12.00 to $8.00 and set a "buy" rating on the stock in a report on Thursday, March 13th.

Insider Buying and Selling at biote

In other news, Director Stephen Mark Cone purchased 38,104 shares of biote stock in a transaction that occurred on Monday, March 17th. The shares were acquired at an average price of $3.88 per share, for a total transaction of $147,843.52. Following the transaction, the director now owns 160,829 shares of the company's stock, valued at approximately $624,016.52. The trade was a 31.05 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Guines Llc acquired 106,000 shares of the firm's stock in a transaction that occurred on Monday, March 31st. The stock was purchased at an average cost of $3.32 per share, for a total transaction of $351,920.00. Following the completion of the purchase, the insider now directly owns 4,033,547 shares of the company's stock, valued at $13,391,376.04. The trade was a 2.70 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 974,110 shares of company stock valued at $3,170,331 in the last three months. Corporate insiders own 24.00% of the company's stock.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.